In an incredible move on Friday, the FDA approved Endari for the treatment of patients age five and older with sickle cell disease to reduce severe complications that are common with the…
Chris Lange The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks shrank.
24/7 Wall St. has conducted a review of the top dividends from America’s largest companies. There were 25 such companies paying a yield of 3.5% or more — and some much higher.
These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500 companies.
The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Cisco, United Technologies, Pfizer, and Merck led the DJIA lower Monday.
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data…
A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow they have for the rest of 2017.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly upward.
These are the top 10 Sell equivalent ratings seen from analysts during the week of May 15 to May 19, 2017 -- plus a bonus that may as well have been a…
UnitedHealth, Nike, Pfizer, and Wal-Mart led the DJIA to a modest decline Tuesday.
The the top analyst upgrades, downgrades and other research calls from Tuesday include AIG, Exact Sciences, MercadoLibre, Pfizer, Whole Foods, Valero Energy and Yum Brands.
Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
Sangamo Therapeutics saw its shares skyrocket early on Thursday after a critical business update.
